The worst session in Moderna’s history
Moderna shares fell as much as 25.2% to $183.88, on course for their steepest one-day percentage drop on record. Merck shares, by contrast, slipped nearly 1%, reflecting how differently the project weighs on the two companies.
The day took an unexpected turn when the trial results leaked on an oncology website earlier in the day, forcing Moderna and Merck to release the data early. That leak set off the wave of selling.
The plunge halted a spectacular rally: Moderna’s stock had risen more than 500% this year as investors bet that the company best known for its COVID-19 vaccine would find a new growth engine in oncology.
Promising trial results
The Phase 3 INTerpath-001 trial enrolled 1,137 patients with high-risk stage IIB to IV melanoma whose tumors had been surgically removed. In August, the companies released interim results showing the trial had met its main goals. The detailed data released on Thursday include the following highlights:
- A 42% reduction in the risk of cancer recurrence or death compared with Keytruda alone
- A 38% reduction in the risk of distant metastasis or death
















